Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (9392)	6/8/1998 8:39:00 PM
From: Y2k_fan	Read Replies (2) \| Respond to of 23519

The shorts will not cover this week, maybe two quarters from now.

To: blankmind who wrote (9392)	6/8/1998 8:40:00 PM
From: Philippe J. Dor	Respond to of 23519

WASHINGTON, June 8 (UPI) - The maker of the just-withdrawn heart drug Posicor tells United Press International (Monday) that the drug's interaction with the impotence pill Viagra could be dangerous, and says he wonders why the Food and Drug Administration is not noting the link publicly. Roche Laboratories says it ''was very upfront with the FDA'' about the Viagra-Posicor danger before announcing the withdrawal, but an FDA spokesperson could not explain why Viagra was not on its list of drugs to be avoided in conjunction with Posicor. dailynews.yahoo.com.

To: blankmind who wrote (9392)	6/8/1998 9:01:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

blankmind, I think we will easily beat $1.00 for FY '99. S&P500 has an average 1999 forward PE of 23. The Q3 numbers will tell us where we are headed for 1999. I think that we will see $2.00+/share for 1999 considering the international markets and substantially reduced production costs. Also, Vivus can get rid of the rental sales force any time it chooses. They will not employ these salespeople if they do not see a substantial effect on the PCPs. PCPs don't necessarily have to prescribe MUSE. If Viagra fails they can let their patient know about MUSE and injections and refer to the urologist. No doubt Viagra will have the biggest piece of the pie. I don't care if they get 50% or 75%, I only want Vivus to have enough of the pie to show some good earnings growth. Q2 will not look pleasant but based on weekly script data we will know where we are heading for Q3 before the Q2 numbers are announced in July.